The article, published in the Journal of Clinical Research & Bioethics, analyzed 22 clinical studies of bupivacaine liposome injectable suspension, including phase III clinical trials and post-market studies and compared them with a medical review of the new drug application from the U.S. Food and Drug Administration.
Access the article here.
More articles on spine:
Can risk sharing work? The realities of reducing low-value spine care
Pedicle subtraction osteotomy revision — 5 things to know
D Magazine honors Spine Team Texas physicians
